Refine
Has Fulltext
- yes (20)
Is part of the Bibliography
- yes (20)
Year of publication
Document Type
- Journal article (20)
Language
- English (20)
Keywords
- HIV (4)
- antiretroviral therapy (3)
- German Hepatitis C-Registry (2)
- chronic hepatitis C (2)
- graft versus host disease (2)
- hepatitis C virus (2)
- infection (2)
- sofosbuvir (2)
- therapeutic drug monitoring (2)
- AIDS (1)
- APRI (1)
- ARDS (acute respiratory distress syndrome) (1)
- BRAF mutation (1)
- COVID-19 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- D insufficiency (1)
- D serum-levels (1)
- FIB-4 (1)
- Germany (1)
- HBV (1)
- HCV cure (1)
- HCV genotype 2 (1)
- HCV genotype-2 (1)
- HCV infection (1)
- HIV diagnosis and management (1)
- HIV infections (1)
- HIV-1-infected patients (1)
- HIV-1-infected subjects (1)
- HIV-infected patients (1)
- IL28B polymorphisms (1)
- LINE-1 retrotransposition (1)
- Prednisolon (1)
- Ruxolitinib (1)
- T cells (1)
- Tansania (1)
- Tanzania (1)
- Uganda (1)
- acoustic radiation force impulse imaging (1)
- active antiretroviral therapy (1)
- adults (1)
- afatinib (1)
- all-cause mortality (1)
- antimicrobial resistance (1)
- antiretrovirals (1)
- at-home sampling (1)
- bile (1)
- biomarkers (1)
- chemokines (1)
- chronic Hepatitis C (1)
- cirrhosis (1)
- coagulation (1)
- common genetic determinants (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- cytotoxic T cells (1)
- dabrafenib (1)
- differentiated thyroid tumor (1)
- direct-acting antiviral (1)
- direct-acting antivirals (1)
- disease (1)
- drug adherence (1)
- drug interactions (1)
- drug monitoring (1)
- drug–drug interactions (DDIs) (1)
- elderly persons (1)
- epidemology (1)
- fibrin D-dimer (1)
- fibrotest (1)
- glecaprevir/pibrentasvir (1)
- healthy volunteers (1)
- highly-active antiretroviral therapy (1)
- human hepatic cells (1)
- hydroxy-dabrafenib (1)
- i-131 uptake (1)
- immune activation (1)
- immune cells (1)
- indinavir (1)
- intensive care medicine (1)
- interferon alpha (1)
- interferon-free (1)
- interleukin-6 (1)
- kinase inhibitors (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liver (1)
- liver diseases (1)
- management (1)
- melanoma (1)
- mutation databases (1)
- non-invasive fibrosis assessment (1)
- osimertinib (1)
- pandemia (1)
- peginterferon alpha-2B (1)
- peginterferon alpha-2b (1)
- pharmacokinetic interaction (1)
- pharmacokinetics (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- plasma D-dimer (1)
- point shear wave elastography (1)
- population pharmacokinetics (1)
- posaconazole (1)
- prostate cancer (1)
- randomized controlled-trial (1)
- real world evidence (1)
- reverse-transcriptase inhibitors (1)
- routine clinical-practice (1)
- ruxolitinib (1)
- sequence databases (1)
- severe fibrosis (1)
- steatosis (1)
- sustained virological response (1)
- therapy (1)
- toxicity (1)
- trametinib (1)
- transient elastography (1)
- viral clearance (1)
- viral load (1)
- viral replication (1)
- virus infection (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- weight gain (1)
Institute
- Medizinische Klinik und Poliklinik II (15)
- Institut für Virologie und Immunbiologie (5)
- Medizinische Klinik und Poliklinik I (5)
- Institut für Pharmazie und Lebensmittelchemie (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Mathematik (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Missionsärztliche Klinik (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 241447 (1)
Using data from the German Hepatitis C-Registry (Deutsche Hepatitis C-Register, DHC-R), we report the real-world safety and effectiveness of glecaprevir/pibrentasvir (GLE/PIB) treatment and its impact on patient-reported outcomes (PROs) in underserved populations who are not typically included in clinical trials, yet who will be crucial for achieving hepatitis C virus (HCV) elimination. The DHC-R is an ongoing, non-interventional, multicenter, prospective, observational cohort study on patients treated for chronic HCV infection in Germany. The data cutoff was 17 January 2021. The primary effectiveness endpoint was sustained virologic response at post-treatment Week 12 (SVR12). Safety outcomes were assessed in all patients receiving GLE/PIB. PROs were assessed using the SF-36 survey. Of 2354 patients, 1964 had valid SVR12 data (intention-to-treat analysis). Of these, 1905 (97.0%) achieved SVR12 with rates similar across the comorbidities analyzed, except for people who actively use drugs (PWUD (active)) (86.4%). Excluding those who discontinued treatment and did not achieve SVR12, or were reinfected with HCV, the rate was 99.3%, with similar results regardless of comorbidity. PWUD (active) and those with psychiatric disorders had the most meaningful improvements in PROs. Adverse events (AEs) occurred in 631/2354 patients (26.8%), and serious AEs in 44 patients (1.9%). GLE/PIB was highly effective and well tolerated in this real-world study of patient groups key to HCV elimination.